GlassScriptPhysician profile
Bruce M Silverman
NPI 1356349062
$27,844.64
in general payments reported to CMS, 2019-2025
58 companies · $2,237 in 2025
The $2,237 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,142 · 2020: $7,232 · 2021: $4,584 · 2022: $845 · 2023: $1,717 · 2024: $2,088 · 2025: $2,237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,678 · Travel and Lodging: $364.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,677.76 |
| Travel and Lodging | $364.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $8,195.93 | 2019-2022 | |
| Biogen, INC. | $7,431.25 | 2019-2020 | |
| Abbvie INC. | $2,584.21 | 2019-2025 | Ubrelvy, Botox, Qulipta |
| Novartis Pharmaceuticals Corporation | $1,625.72 | 2019-2025 | |
| Emd Serono, INC. | $1,172.10 | 2019-2024 | Mavenclad |
| Genzyme Corporation | $921.30 | 2019-2023 | |
| Ucb, INC. | $707.57 | 2022-2025 | Briviact, Rystiggo, Nayzilam |
| Teva Pharmaceuticals USA, INC. | $499.73 | 2019-2024 | Austedo Xr |
| Lundbeck LLC | $391.74 | 2020-2025 | Vyepti, Rexulti |
| Eisai INC. | $371.46 | 2023-2025 | |
| Celgene Corporation | $295.86 | 2021-2025 | Zeposia |
| Pfizer INC. | $290.48 | 2021-2025 | |
| Avanir Pharmaceuticals, INC. | $259.15 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $240.37 | 2019-2025 | Ultomiris, Soliris |
| Neurelis, INC. | $165.98 | 2022-2025 | Valtoco |
Show all 57 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Silverman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.